
Consumer Staples / Healthcare · BSE
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and nutraceutical products across multiple dosage forms such as tablets, capsules, oral liquids, powders, oils, and external applications including balms, creams, and gels, operating as a Contract Development and Manufacturing Organization (CDMO) for both domestic and international markets including Sri Lanka, Singapore, and the USA. The company blends classical Ayurvedic formulations with modern nutraceutical science to address wellness segments such as liver care, women’s health, bone and joint health, cognitive support, and respiratory health, with its revenue primarily driven by domestic sales and merchant exports on a loan license basis, along with a growing contribution from direct exports. It operates a 10,763 sq. ft. manufacturing facility in Gujarat equipped with modern infrastructure, multiple air handling units, segregated processing areas, and quality control systems, and holds certifications including GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, Halal, and FSSAI.
Price Band
₹122 – ₹129
Issue Size
₹24.77 Cr
Lot Size
1000 shares
GMP
+20.9%
Est. Listing
₹156
at current GMP
Subscribed
1.91x
overall
Open
28 Jan 2026
Close
30 Jan 2026
Allotment
2 Feb 2026
Refund
3 Feb 2026
Demat Credit
4 Feb 2026
Listing
4 Feb 2026
Designated Registrar: Kfin Technologies Limited
Allotment Date
2 Feb 2026
Basis finalization
Refunds Initiate
3 Feb 2026
Mandate release
Demat Credit
4 Feb 2026
Shares in demat
Listing Debut
4 Feb 2026
Trading begins
Accretion Nutraveda Limited is bringing an initial public offering (IPO) in the Consumer Staples / Healthcare sector with an aggregate issue size of ₹24.77 Crores. The shares are offered at a price band of ₹122 to ₹129 per equity share on BSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 1000 shares (approx. ₹1,29,000 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Kfin Technologies Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2026-02-04, while un-allotted funds or UPI block mandates will be released on 2026-02-03.
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.